This week, cannabis coverage focused on federal reclassification impacts, clinical research into CBD and cannabinoids for health conditions, and regulatory policy updates.
Friday, March 13, 2026 — top 5 across News, Studies, Policy, and Memes
Marijuana reclassification may require changes to drug testing protocols for private pilots and other safety-sensitive occupations.
Marijuana reclassification may impact drug testing for private pilots | FOX 13 Tampa Bay →
New Hampshire’s House failed to vote on marijuana legalization and psilocybin therapy bills, delaying potential clinical pathways for treating mental health conditions.
New Hampshire House Lets Marijuana Legalization And Psilocybin Therapy Bills Die Without A Vote →
Patients with legitimate medical cannabis use are calling for global legal reform to prevent arrest when traveling across borders with their medication.
Patients Call For Global Medical Cannabis Laws To End Border Arrests – Forbes →
This guide explains how clinicians and patients can interpret cannabis certificates of analysis in Florida to understand cannabinoid content, dosing, and safety information.
A Beginner’s Guide to Reading Cannabis Certificates of Analysis in Florida →
A March 2026 cannabis news roundup featuring three articles, including Trulieve’s plan to open a medical cannabis dispensary in DeLand, Florida.
A clinical trial found that single doses of CBD (30 mg and 700 mg) did not alter cortical excitability in healthy males compared to placebo.
Cannabidiol & Cortical Excitability: Clinical Trial Findings →
A pilot trial found that a single 10 mg THC and 200 mg CBD dose reduced total sleep time in insomnia patients compared to placebo.
Cannabis flower and edible products show different same-day anxiety reduction effects based on their THC and CBD composition ratios.
A randomized controlled trial found that cannabidiol did not significantly reduce fibromyalgia pain compared to placebo, providing no evidence for its effectiveness as a standalone treatment.
The REAL 2.0 study tracked Canadian youth over 15 years to examine how adolescent body image and eating disorders correlate with mental health and substance use outcomes.
This piece summarizes 16 cannabis-related regulatory updates from March 13, 2026, ranked by relevance, sourced from Federal Register and regulations.gov.
Summary
The DEA schedules 2-Methyl AP-237, a synthetic opioid analogue, as a Schedule I controlled substance due to emerging safety concerns and lack of accepted medical use.
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I →
The DEA placed three synthetic opioids (butonitazene, flunitazene, and metodesnitazene) into Schedule I of the Controlled Substances Act due to emerging public health concerns.
The DEA places three synthetic opioids (etodesnitazene, N-pyrrolidino etonitazene, and protonitazene) into Schedule I controlled substances classification.
I cannot provide an accurate summary of this piece because the excerpt appears incomplete and does not contain substantive content about the stated topic of firearms dealer regulations.
Definition of Engaged in the Business as a Dealer in Firearms →
This piece humorously discusses the need for better clinical trials and individualized dosing protocols before widespread cannabinoid therapy can be confidently recommended for symptom relief.
Summary
This piece explains that cannabinoids require liver metabolism through P450 enzymes to become bioactive, despite the endocannabinoid system’s appreciation for cannabis compounds.
This piece discusses cannabinoids as a treatment option, references clinical trials on cannabis for anxiety relief, and covers cannabis-infused beverages as alcohol alternatives in New York.
Summary
A couple with chronic pain use cannabis together and find their relationship improves when both understand each other’s need to cancel plans due to pain management.
This piece highlights Jacob Witzling’s cannabis craftsmanship, suggesting his work demonstrates scientific understanding of endocannabinoid systems rather than relying on superficial knowledge.
Digest-Level Clinical Commentary
Clinical Reflection
The digest reflects a field in transition: while regulatory frameworks remain fragmented across jurisdictions (affecting patient access and clinical standardization), emerging clinical trial data on cannabinoids for insomnia and anxiety show promise but require careful dose titration and acknowledgment of mixed outcomes, as evidenced by CBD’s lack of superiority in fibromyalgia trials. As practitioners, we must navigate this complex landscape by staying current with both the evolving evidence base and the regulatory-policy shifts that determine what medications we can legally recommend and what documentation our patients may face across borders or in safety-sensitive occupations.
Clinical Perspective
This digest reflects a field in transition, with concurrent policy developments and clinical evidence generation that clinicians must navigate carefully. The research items highlight mixed findings on cannabinoid efficacy for specific conditions like insomnia, anxiety, and fibromyalgia, underscoring the need for evidence-based patient counseling rather than assumption of benefit. Regulatory changes regarding cannabis scheduling and related substances, along with international legal disparities, create practical challenges for clinicians advising patients on safety, drug testing implications, and treatment options.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
